ストックスクリーナーアプリを入手
4.505
8.03%
0.335
アフターアワーズ：
4.50
-0.005
-0.11%
前日終値:
$4.17
開ける：
$4.17
24時間の取引高:
127.39K
Relative Volume:
0.73
時価総額：
$134.04M
収益：
-
当期純損益:
$-13.08M
株価収益率:
-10.20
EPS:
-0.4416
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.91%
1か月 パフォーマンス:
-0.33%
6か月 パフォーマンス:
+34.88%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.17
$4.62
1週間の範囲:
$4.1401
$5.02
52週間の値動き範囲:
$3.11
$20.72
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
TELO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
4.505 | 134.04M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
TELO Treatment Amazes in Preclinical Trial - MSN
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts? - Barchart
Telomir Pharmaceuticals Announces Major Breakthrough in Reversing Oxidative Stress, Unlocking Potential for Treating Age-Related Diseases and Viruses Like Bird Flu - Barchart
Thrombotic Thrombocytopenic Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc - Barchart
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Triple Negative Breast Cancer Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs - Barchart
Advanced Liver Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight - Barchart
Telomir Pharmaceuticals Announces Breakthrough Results with Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as A Treatment for Avian Influenza (Bird Flu) and Other Viruses - Marketscreener.com
Thumzup Media (NASDAQ: TZUP) Reports 230% Advertiser Growth, Expands National Presence - Barchart
Stocks In Play: NextSource Materials Inc. - Barchart
Telomir touts potential of Telomir-1 in addressing oxidative stress - MSN
Stocks In Play: CGI Inc. - Barchart
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Pancreatic Cancer Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma - Barchart
Pharma company reports potential of 'age-reversal' molecule - The Business Journals
Telomir Pharmaceuticals reports reversal of oxidative stress - MSN
Telomir Pharmaceuticals reports reversal of oxidative stress By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses - ACCESS Newswire
Telomir touts potential of Telomir-1 in addressing oxidative stress (TELO:NASDAQ) - Seeking Alpha
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 - ACCESS Newswire
Barclays PLC Purchases 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December - MarketBeat
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners are retail investors who got richer after stock soared 13% last week - Yahoo Finance
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded - Simply Wall St
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
Barclays PLC Buys 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Geode Capital Management LLC Has $1.53 Million Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Stocks In Play: Almonty Industries Inc. - Barchart
Telomir Pharmaceuticals reports breakthrough in progeria study By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals confirms lifespan restoration in Progeria preclinical model with Telomir-1 - MSN
Telomir Pharmaceuticals reports breakthrough in progeria study - Investing.com
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging) - AccessWire
Renovaro Appoints Nathen Fuentes as Chief Financial Officer - GlobeNewswire
State Street Corp Acquires 17,967 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Elon Musk Weighs In On Weight-Loss Drug Stocks. Is LLY Or NVO A Better Buy? - Barchart
Charles River Laboratories Stock: Is CRL Underperforming The Healthcare Sector? - Barchart
Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Expands By 22.9% - MarketBeat
Telomir Pharmaceuticals Confirms Copper-Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson’s Disease - Defense World
Telomir Pharmaceuticals Expands Pipeline, Confirms Copper-Binding Potential of Telomir-1 for Wilson’s Disease - ChemAnalyst
Telomir-1 shows promise in copper binding studies - Investing.com
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease - Chronicle-Tribune
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease - Yahoo Finance
Telomir Pharmaceuticals appoints new accounting firm - Investing.com India
Telomir Pharmaceuticals Raises $1 Million in Premium-Priced Stock Deal, Boosting Age-Reversal Research - Citybuzz
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation - Nasdaq
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
Telomir Pharmaceuticals enters into stock purchase agreement - MSN
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Telomir Pharmaceuticals secures $1 million equity funding - Investing.com
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - AccessWire
Telomir Pharmaceuticals Inc (TELO) 財務データ
収益
当期純利益
現金流量
EPS
4.02%
0.32%
大文字化:
|
ボリューム (24 時間):